Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Kyntra Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.019 and thank you for standing by. Welcome to the Kentra Bio first quarter 2026 earnings 00:00:05.019 -- 00:00:09.566 conference call. At this time, all participants are on a listen-only mode. 00:00:09.566 -- 00:00:12.891 After the speaker's presentation, we'll open up for questions. 00:00:12.891 -- 00:00:17.357 To ask a question during the session, you will need to press star 1-1 on your telephone. 00:00:17.357 -- 00:00:20.863 You will then hear an automated message advising your hand is raised. 00:00:20.863 -- 00:00:24.348 To withdraw your question, please press star 1-1 again. 00:00:24.348 -- 00:00:27.052 Please be advised that today's call is being recorded. 00:00:27.052 -- 00:00:32.798 I would now like to hand it over to our first speaker, Dalia, Seamus, please go ahead. 00:00:32.798 -- 00:00:37.604 Thank you, Victor. Good afternoon, everyone, and thank you for joining us today to discuss 00:00:37.604 -- 00:00:42.671 Kintra Bio's first quarter of 2026 financial and business results. 00:00:42.671 -- 00:00:45.374 I'm Dalia Seamus from LifeSciAdvisors. 00:00:45.374 -- 00:00:51.082 Joining me on today's call are Thayne Wettig, Chief Executive Officer, David DeLucia, 00:00:51.082 -- 00:00:56.883 Chief Financial Officer, and Carol Gatham, Vice President of Product Development. 00:00:56.883 -- 00:01:01.089 Following the preferred remarks, we will open the call to your questions. 00:01:01.089 -- 00:01:05.315 I would like to remind you that remarks made on today's call include forward-looking 00:01:05.315 -- 00:01:07.898 statements about intrabio. 00:01:07.898 -- 00:01:12.945 Such statements may include, but are not limited to, collaborations with AstraZeneca 00:01:12.945 -- 00:01:18.052 and Astellas, financial guidance, the initiation, en...